Drug Profile
Ab 01.12
Alternative Names: Ab 01; Ab-01.12; PNEUMONAVLatest Information Update: 12 May 2023
Price :
$50
*
At a glance
- Originator Abera Bioscience AB
- Developer Abera Bioscience AB; Radboud University
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Pneumococcal infections
Most Recent Events
- 02 May 2023 Phase-I clinical trials in Pneumococcal infections (Prevention) in Netherlands (Intranasal)
- 25 Apr 2023 Abera Bioscience plans a phase I trial for Pneumococcal infections (Prevention) in Netherlands H1 2023
- 25 Apr 2023 Adverse events and immunogenicity data from a preclinical study in Pneumococcal infections released by Abera Bioscience